NL-OMON48973已完成3 期
A Phase III Open Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study - SIDEROS-E
Santhera Pharmaceuticals (Switzerland),0 个研究点目标入组 11 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 99（—）
入选标准
- •Completion of the SIDEROS study at Visit 8/ Week 78.
- •Signed and dated Informed Consent Form.
排除标准
- •Patients who discontinued SIDEROS study prematurely (i.e. did not attend all
- •visits from V1 to V8).
- •Safety, tolerability or other issues arising during the course of the SIDEROS
- •study which in the opinion of the Investigator may put the patient at
- •significant risk or may interfere significantly with the patient's
- •participation in the SIDEROS-E study.
- •Use of any investigational drug other than the study medication.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.Pseudomonas aeruginosa infection in cystic fibrosis patientsMedDRA version: 13.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004764-39-LTovartis Pharma Services AG100
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.Duchenne Muscular Dystrophy (DMD)MedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004279-30-SESanthera Pharmaceuticals (Switzerland) Limited266
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.Duchenne Muscular Dystrophy (DMD)MedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004279-30-NLSanthera Pharmaceuticals (Switzerland) Limited266
进行中（未招募）
1 期
A clinical study to assess the long-term safety and efficacy of idebenone treatment in patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study.Duchenne Muscular Dystrophy (DMD)MedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-004279-30-ESSanthera Pharmaceuticals (Switzerland) Limited266
进行中（未招募）
不适用
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.Pseudomonas aeruginosa infection in cystic fibrosis patientsMedDRA version: 12.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaEUCTR2008-004764-39-BGovartis Pharma Services AG100